Popular Articles

Senate Could Vote Today On Tougher Tobacco Legislation
The Senate could vote today on tougher tobacco laws that would give the Food and Drug Adminstration power to regulate tobacco.
generic viagra online
Cooling Therapy For Cardiac Arrest Survivors Is As Cost-Effective As Accepted Treatments For Other Conditions
Cooling unconscious cardiac arrest survivors can increase survival and has a cost effectiveness comparable to other widely accepted treatments in modern health care, researchers report in Circulation: Cardiovascular Quality and Outcomes.
News of the day
GM, UAW Nearing Deal To Use Company Stock For Half Of VEBA Obligation, s Say
General Motors and the United Auto Workers are close to finalizing a deal that would reduce the automaker"s cash obligation to a retiree health care trust fund, according to people with knowledge of the matter, the Wall Street Journal reports. UAW in 2007 agreed to establish the voluntary employees" beneficiary association, totaling $35 billion, that would cover health care costs of retired GM workers and their spouses starting in 2010. GM has paid about $15 billion into the fund, but under the deal now being discussed, the remaining $20 billion obligation could be paid using about $10 billion in cash and a 39% equity stake in the restructured GM that will be formed under the Treasury Department"s "controlled bankruptcy" plan for the firm. The deal would be subject to approval by UAW"s 60,000 GM members, who likely would face "steep cuts" in pay and benefits as a result, as well as 20,000 additional layoffs, according to the Journal. Union officials also have expressed concern that the GM stock making up the equity stake is "illiquid and hard to value, posing a big risk for UAW members," the Journal reports. GM and UAW could agree to a final version of the deal "as early as next week," according to the Journal (Stoll, Wall Street Journal, 5/15). Chrysler
Diagnostics

CytoDyn Completes Safety Testing Of Cytolin(R): Benchmark For Improved Treatment Of HIV/AIDS

CytoDyn, Inc. (Pink Sheets:CYDY) has completed safety testing of its current inventory of Cytolin®, the Company"s immune-system modulator for managing HIV disease and the public health crisis afflicting communities where the infection is spreading due to unprotected sex and the other risk factors for AIDS. Tests for specific adventitious agents and other quality parameters following purification were performed by the manufacturing facility, Vista Biologicals Corporation of Carlsbad, California. The other safety tests, including in vivo general safety using two animal species, were performed by WuXi AppTec, a fully integrated pharmaceutical, biotechnology and medical-device company with facilities in St. Paul, Minnesota. WuXi AppTec provides R&D services to the biotechnology industry. Since the product is intended for use in a clinical trial, the tests conducted were those required for each new batch of a biologic agent manufactured for use in human research. The Company believes that the test results satisfy the current safety standards for the manufacturing of drugs belonging to the class of biologics. The results are summarized in the table below. About Safety Testing Product safety testing evaluates the quality of the manufacturing process in order to avoid risks to the health of human subjects that can arise from the way a particular lot of a drug was manufactured. The intrinsic safety of a drug intended for use in humans can only be ascertained from the response of human subjects to that drug. In previous human studies, multiple infusions of Cytolin® were well tolerated, as reported in a newly released documentary Conference on Retroviruses and Opportunistic Infections (CROI) by the Principal Investigator, Donald W. Northfelt, MD, then at the Eisenhower Medical Center in Palm Desert, California. Cytolin®


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):